Aciclovir Belupo, 400 mg 21 pcs

Acyclovir is an antiviral drug, a synthetic analog of acyclic purine nucleoside, which has a highly selective effect on herpes viruses. A series of sequential reactions of acyclovir transformation into mono-, di- and triphosphate acyclovir takes place inside virus-infected cells under the action of viral thymidine kinase. In vitro acyclovir is effective against herpes simplex virus – Herpes simplex type I and II, against Varicella zoster virus; higher concentrations are required for inhibition of Epstein-Barr virus.

In vivo acyclovir is therapeutically and prophylactically effective primarily in viral infections caused by Herpes simplex.

Pharmacokinetics: When taken orally bioavailability is 15-30%. Acyclovir penetrates well into all organs and tissues of the body, including the brain and skin. Binding to plasma proteins is 9-33% and does not depend on its concentration in plasma. Concentration in cerebrospinal fluid is about 50% of its concentration in plasma. Acyclovir penetrates the placental barrier and accumulates in breast milk. Cmax after oral administration of 200 mg 5 times a day is 0.7 mcg/ml, Tmax is 1.5-2 h.

Metabolized in the liver to form pharmacologically inactive compound 9-carboxymethoxymethylguanine. T1/2 in adults with normal renal function is 2-3 hours.

In patients with severe renal insufficiency T1/2 is 20 hours, with hemodialysis – 5.7 hours (with acyclovir plasma concentration decreases to 60% of the initial value).

About 84% is excreted unchanged in the kidneys and 14% – as a metabolite. Renal clearance of acyclovir is 75-80% of the total plasma clearance. Less than 2% of acyclovir is excreted from the body through the intestine.

Indications

Active ingredient

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Pregnancy use

Similarities